CClinicalTrials.gg
Not yet recruitingNCT07067957Updated Jul 16, 2025

Prevalence of Functional Lower Urinary Tract Voiding Dysfunction in School-Aged Children

An observational study in Voiding Dysfunction, Urinary Incontinence and Urination Disorders, sponsored by Tanta University. Not yet recruiting at 1 site in Egypt. Open to participants aged 4 Years to 14 Years. Per ClinicalTrials.gov, last updated 2025-07-16.

Sponsored by Tanta University · Observational

From the registry’s dates

  • Primary completion was expected by Nov 2025, 10 months ago, but the record still lists the study as not yet recruiting.
Study type
Observational
Model
Cohort
Time perspective
Cross-sectional
Enrollment
500
Ages
4 Years to 14 Years
Sex
All
01

Study summary

The aim of this study is to investigate the prevalence of voiding disorders and the related risk factors for the primary school-age children in El Ghrbia Government

Read the detailed description

Lower urinary tract dysfunction (LUTD) is classified as a storage and voiding symptoms. Storage symptoms are increased or decreased urinary frequency, urinary incontinence, urinary urgency, and nocturia. Voiding symptoms are classified as hesitation, straining, weak stream, and intermittency. Other symptoms are holding maneuvers, feeling of incomplete emptying, postmicturition dribble, and genital and lower urinary tract pain. Constipation and/or fecal incontinence are closely related to LUTD, among children over 5 years due to functional or nonorganic causes.

The exact prevalence of the lower urinary tract dysfunction (LUTD) is unknown, approximately 20% to 30% of children in the world have symptoms associated with voiding disorders. In epidemiological studies, this ratio is between 2.1% and 19.2% in school-age children.Due to the modern lifestyle, the prevalence increases secondary to changes in toilet training and habits.

02

Conditions studied

  • Voiding Dysfunction
  • Urinary Incontinence
  • Urination Disorders
  • Lower Urinary Tract Symptoms
  • Pediatrics
  • Constipation
03

In context

Urinary Incontinence

1,363 studies on the registry are indexed under Urinary Incontinence; 228 are open to participants now.

This study's planned enrollment of 500 is above the median of 120 across 305 observational studies indexed under Urinary Incontinence.

Browse Urinary Incontinence studies →

Lead sponsor

Tanta University is the lead sponsor of 963 studies on the registry; 304 are open to participants now.

Of its 16 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
4 Years to 14 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

School-aged children (4-14 years) attending primary schools in El Gharbia Governorate, Egypt, during the study period.

Inclusion criteria

  • Children aged 4-14 years old in our locality.

Exclusion criteria

Exclusion Criteria:

  • Children with known anatomical anomalies of urinary tract
  • Children with known neurological anomalies (spinal dysraphism, multiple sclerosis, lumbar or spinal neuritis……… etc)
  • Children with history of back or lower urinary tract trauma
  • Parents who refuse participation
05

Study design

Observational model
Cohort
Time perspective
Cross-sectional
Enrollment
500 participants (estimated)
Patient registry
No

Groups and cohorts

  • Study group

    School-aged Children

    Other: Arabic Dysfunctional Voiding Symptom Score Questionnaire (DVSS)

Interventions

  • OtherArabic Dysfunctional Voiding Symptom Score Questionnaire (DVSS)

    A validated Arabic version of the Dysfunctional Voiding Symptom Score Questionnaire (DVSS) questionnaire will be used to screen children for symptoms of lower urinary tract dysfunction. It includes 10 items assessing urinary and bowel habits.

06

What researchers measure

Primary outcomes

  1. Prevalence of Voiding Dysfunction

    Prevalence of Voiding Dysfunction Among School-Aged Children will be Measured using the validated Arabic version of the Dysfunctional Voiding Symptom Score (DVSS). Children with a score above the diagnostic threshold will be considered as having voiding dysfunction.

    Time frame: 1 Hour after completion of the questionnaire

Secondary outcomes

  1. Frequency of Constipation in Children With Voiding Dysfunction

    Constipation history will be identified through the Dysfunctional Voiding Symptom Score (DVSS) questionnaire and confirmed during clinical evaluation.

    Time frame: 1 Hour after completion of the questionnaire

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Yes — The data will be available upon a reasonable request from the corresponding author after the end of study for one year.

Supporting information: Study protocol

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 16, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07067957
Lead sponsor
Tanta University
Responsible party
Mohamed Ibrahim Ahmed Elmaadawy (Lecturer of Urology, Faculty of Medicine, Tanta University, Tanta, Egypt., Tanta University) — Principal investigator
First posted
Jul 16, 2025
Start date
Jul 10, 2025 (estimated)
Primary completion
Nov 30, 2025 (estimated)
Completion
Nov 30, 2025 (estimated)
Last update
Jul 16, 2025

Study contacts

Mohamed I Elmaadawy, MD
Contact
Mohamed.elmaadawy@med.tanta.edu.eg
00201060245430

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion